Source: International Congress 2015 – Quality management in lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Niels-Christian Gerner Hansen (Odense C, Denmark), Niels-Chr. G. Hansen, Christian B. Laursen, Karin H. Hansen, Karen E. Olsen. Epithelial growth factor receptor (EGFR) mutation status and the treatment of non-small cell lung cancer (NSCLC): A population based quality assurance analysis. Eur Respir J 2015; 46: Suppl. 59, 4222

Member's Comments

No comment yet.

Related content which might interest you: Simvastatin overcomes gefitinib resistance in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor via Akt/b-catenin signaling dependent down-regulation of survivin Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer Source: Eur Respir J 2011; 38: 903-910 Year: 2011 Characterization of patients with non-small cell lung cancer (NSCLC) relative to its EGFR mutational status Source: Annual Congress 2011 - Epidemiology of lung cancer and screening Year: 2011 Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015 Epidermal growth factor receptor mutation status in advanced non-small cell lung cancer: A single institution experience Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 Evaluation of the role of EGFR as prognostic factor in stage III non-small cell lung cancer (NSCLC): a retrospective analysis Source: Eur Respir J 2004; 24: Suppl. 48, 478s Year: 2004 Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study Source: Eur Respir J 2007; 29: 128-133 Year: 2007 Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis Source: International Congress 2018 – Lung cancer: modern therapies and beyond Year: 2018 Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 Tumour growth rate as a tool for response evaluation during PD-1 treatment for non-small cell lung cancer: a retrospective analysis Source: ERJ Open Res, 5 (4) 00179-2019; 10.1183/23120541.00179-2019 Year: 2019 The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer Source: Eur Respir Rev 2010 19: 186-196 Year: 2010 Targeting gene of insulin-like growth factor type I (IGF-I) on in vitro model of A549 cell line with triple-helix approach. Perspectives of gene therapy in non-small cell lung (NSCLC) cancer Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006 Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer. Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology Year: 2020 Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Actual challenges in thoracic surgery Year: 2010 EGFR frequency and response to chemotherapy in a Brazilian NSCLC population Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life Year: 2013 EGFRmutations are associated with higher brain metastasis radio-sensitivity than KRAS mutations or wild type EGFR in non-small cell lung cancer patients (NSCLC) Source: International Congress 2014 – Therapy of thoracic tumours: clinical trials and case series Year: 2014 Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 811s Year: 2006 A tissue microarray analysis on the role of chromosome 7 multiplication regarding the EGFR expression in non-small cell lung carcinomas Source: International Congress 2016 – Molecular targets in pulmonary disease Year: 2016 Prognostic value of survivin gene promoter polymorphisms in non-small cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer I Year: 2016 Retrospective study of treatment outcomes according to exon difference with EGFR mutations in non-small cell lung cancer patient in Korea Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012